GLUE · Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics reported its first quarter 2026 financial results, highlighting a net loss of $44.5 million compared to net income of $46.9 million in the same period last year. The swing was driven by a significant decrease in collaboration revenue ($4.2 million vs $84.9 million) and a 37% increase in R&D expenses to $44.1 million, reflecting investment in the MRT-8102 program and other pipeline candidates. G&A expenses rose to $10.2 million from $8.7 million. The company ended the quarter with $671.2 million in cash and marketable securities, bolstered by a $345 million public offering in January, providing runway into 2029. Operationally, Monte Rosa reported positive interim data for its NEK7-directed MGD MRT-8102, showing 85% CRP reduction in elevated CVD risk subjects, and plans to initiate multiple Phase 2 studies in H2 2026. The GSPT1-directed MRT-2359 demonstrated a 100% disease control rate in mCRPC patients with AR mutations, with a Phase 2 study planned for Q3 2026. The VAV1-directed MRT-6160 is advancing toward Phase 2 initiation by Novartis. Additionally, an IND submission for a cyclin E1-directed MGD is expected in H2 2026. The strong cash position and advancing pipeline underscore the company's ability to execute on its clinical development plans.